Preliminary Programme

Thursday, March 28, 2019
13:00 - 19:00 REG Working Group Meetings
Friday, March 29, 2019
08:00 - 08:45 REG Supporters Meeting
08:50 - 09:00 Welcome
09:00 - 10:30 COPD: Should Patients with severe COPD be treated with ICS? Pro and Con
10:30 - 11:00 Coffee break
11:00 - 12:00 Role of immunotherapy in asthma:
- AIT & Asthma in daily practice around the world
- Responders and non-responders to AIT for asthma
- Future long-term AIT studies in adults with asthma
12:00 - 12:30 Maximizing the First International Severe Asthma registry for Research
12:30 - 13:30 Lunch break
13:30 - 14:00 Interstitial Pulmonary Fibrosis: Does early treatment make a difference?
14:00 - 15:00 New paradigms in mild asthma: Regular ICS therapy is better than prn ICS/LABA in in mild asthma? Pro and Con
15:00 - 15:30
Coffee break
15:30 - 17:00 Controversies in pediatric asthma:
The term “preschool wheeze” should be abandoned? Pro and Con
The limits and distribution of asthma severity in kids: where should we draw the line?
Next-generation Guidelines: are phenotype/endotype-based recommendations feasible/preferable?  Pro and Con
17:00 - 17:40 Treatable traits: perspectives from a specialist and GP
17:40-18:10 Inhaler technique and adherence
18:15 - 19:00 REG AGM
19:00 - 22:00 Networking Event
Saturday, March 30, 2019
08:30 - 09:00 Vaccinating your respiratory patient
09:00 - 10:30 Severe asthma: the evolving algorithm of biological selection in severe asthma creating an algorithm for care 
Panel Discussion
1. General overview of severe asthma
2. No biologic treatment
3. Treatment with IL5
4. Treatment with anti- IGE
5. Treatment with anti IL4/13
10:30 - 11:00 Coffee break
11:00 - 12:00
Keynote: Real-life research and its role in the future
12:00 - 13:00 Potential of RWE in regulatory decisions  Panel Discussion
13:00 Meeting close followed by lunch